Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion
NCT ID: NCT03044093
Last Updated: 2017-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
200 participants
INTERVENTIONAL
2017-01-31
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Misoprostol for Second Trimester Termination of Pregnancy
NCT00945997
Misoprostol vs. Sublingual Misoprostol and Laminaria For Second Trimester Termination of Pregnancy
NCT02013960
Mifepristone Plus Misoprostol Versus Misoprostol Alone for 2nd Trimester Abortion (14 - 21 Weeks Last Menstrual Period (LMP))
NCT00969982
Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion.
NCT03440866
Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone
NCT00680394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MISOPROSTOL alone
the common practice currently in our medical center for second trimester medical abortion/ Placebo
Placebo
The group that will only get Misoprostol
Misoprostol
Both groups will get think drug
Mifepristone and Misoprostol
in addition to the common practice currently in our medical center for second trimester medical abortion we will add Mifepristone before administering Misoprostol.
Mifepristone
Mifepristone
The group that will get in addition to Misoprostol also Mifepristone
Misoprostol
Both groups will get think drug
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mifepristone
The group that will get in addition to Misoprostol also Mifepristone
Placebo
The group that will only get Misoprostol
Misoprostol
Both groups will get think drug
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* no allergy known to these drugs
* second trimester abortion
Exclusion Criteria
* clotting factor deficiency
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rambam Health Care Campus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rambam Medical Campus
Haifa, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
MEIR NIZRI, MD
Role: CONTACT
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
MEIR NIZRI, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0299-16-RMB
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.